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LETTER TO EDITOR Open Access
Rare gene fusion rearrangement SPTNB1-
PDGFRB in an atypical myeloproliferative
neoplasm
Vanessa Fiorini Furtado1* , Neeraj Y. Saini2, William Walsh2, Venu Bathini2† and Patricia M. Miron3†
Abstract
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia recognizes
a distinct class of myeloid and lymphoid tumors with eosinophilia-related proliferations associated with specific gene
rearrangements, one of which involves rearrangements of platelet-derived growth factor receptor B (PDGFRB) gene.
We report a case of a rare PDGFRB rearrangement with SPTNB1 (spectrin beta, nonerythrocytic 1) that presented as
atypical myeloproliferative neoplasm.
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Dear Editor,
The 2016 revision to the World Health Organization
classification of myeloid neoplasms and acute leukemia
recognizes a distinct class of myeloid and lymphoid tu-
mors with eosinophilia-related proliferations associated
with specific gene rearrangements, one of which involves
rearrangements of platelet-derived growth factor recep-
tor B (PDGFRB) gene [1]. More than 30 fusion partners
of PDGFRB gene have been reported [2]. Although un-
common, they are important for diagnosis and treatment
[3–8]. We report a case of a rare PDGFRB rearrange-
ment with SPTNB1 (spectrin beta, nonerythrocytic 1)
that presented as atypical myeloproliferative neoplasm.
A 76-year-old male presented with progressively wors-
ening of dyspnea on exertion and complete blood count
revealed macrocytic anemia (hemoglobin 8.3 mg/dl),
monocytosis and lymphopenia. Etiology was not delin-
eated at the time, but subsequently the patient became
transfusion dependent. His bone marrow was consistent
with myeloproliferative disease with hypercellularity and
increased myeloid:erythroid ratio of 5:1 with a promin-
ent granulocytic hyperplasia associated with eosinophilia
(24%). Remarkably, peripheral blood (PB) eosinophil
counts were normal. BCR-ABL rearrangement was not
detected by fluorescence in situ hybridization (FISH) of
PB.
Cytogenetic analysis of bone marrow revealed 16/20
cells to represent an abnormal clone with a (2;5) trans-
location: 46,XY,t(2;5)(p21;q33)[16]/46,XY [4] (Fig. 1a).
Interphase FISH evaluation for PDGFRB rearrangement
was performed with a PDGFRB Break Apart probe
(Kreatech Diagnostics, Inc./Leica Biosystems, Buffalo
Grove, IL) at 5q33; rearrangement was observed in 85/
100 nuclei (Fig. 1b). Based on a single previous report of
a t(2;5)(p21;q33) that was determined to represent an
SPTBN1/PDGFRB fusion, FISH was performed to assess
possible involvement of SPTBN1. Two BAC probes,
RP11-378O10 and RP11-564H16 (Empire Genomics,
Buffalo, NY) that together span a 310 kb region contain-
ing SPTBN1 (Fig. 1d) were hybridized to both metaphase
and interphase cells. Interphase FISH showed rearrange-
ment (splitting) of RP11-5644H16 in 75/100 nuclei;
metaphase FISH showed RP11-5644H16 to be split with
signal on both the derivative 2 and the derivative 5, and
RP11-378O10 to be translocated entirely to the deriva-
tive chromosome 5 (Fig. 1c). Thus, the chromosome 2
breakpoint is within the SPTBN1 gene. To our know-
ledge, this is only the second report of an SPTBN1/
PDGFRB rearrangement. Of note, rearrangement of
SPTBN1 with other partner genes also has been reported
rarely [9, 10].
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Imatinib mesylate 200 mg daily was initiated. After
3 months of therapy, patient achieved complete
hematological response and became transfusion inde-
pendent. His dose of imatinib was tapered to 200 mg
weekly in 1 year and patient has remained in
hematological remission for more than 3 years. Al-
though imatinib was originally designed as a specific
inhibitor of the BCR-ABL tyrosine kinase, it has been
shown to be effective toward PDGFRB-associated
MPN [3, 4, 6, 7]. Prior study reported 10-year OS of
90% in patients with myeloid malignancies bearing
PDGFRB fusion genes who were treated with imatinib
[4]. Furthermore, achievement of rapid and durable
complete cytogenetic and molecular responses on
doses lower than 400 mg, suggests that patients with
PDGFRB rearrangements may be more sensitive to
imatinib [4]. Our case report highlights the exquisite
sensitivity of PDGFR gene fusion rearrangement to
imatinib in patients with myeloid malignancies and
suggests lower weekly doses of imatinib can be con-
sidered in this patient group.
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Fig. 1 a Karyogram showing translocation t(2;5)(p21;q33). b FISH analysis with a PDGFRB break-apart probe on interphase nuclei showing one
normal intact fusion signal and one split signal (one red, one green) confirming PDGFRB gene rearrangement. c Metaphase FISH showing RP11-
5644H16 to be split with signal on both the derivative 2 and the derivative 5, and RP11-378O10 translocated to the derivative chromosome 5.
d Map of BAC probes relative to SPTBN1 gene. Direction of SPTBN1 transcription is towards the centromere on chromosome 2
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